Table 1.
Baseline characteristics of patients with RA (n = 320).
| Mean ± SD or n (%) | |
|---|---|
| Age, years | 60.5 ± 9.8 |
| Male, n (%) | 20 (6.6) |
| Postmenopause, n (%) | 259 (86.3) |
| Body weight, kg | 57.8 ± 10.0 |
| Height, cm | 156.7 ± 6.4 |
| BMI, kg/m2 | 23.5 ± 3.7 |
| Smoker, n (%) | 21 (6.0) |
| Duration of RA, months | 104.5 ± 67.5 |
| Hypertension, n (%) | 85 (26.6) |
| Dyslipidemia, n (%) | 104 (32.5) |
| Diabetes, n (%) | 26 (8.1) |
| Tender joint count | 3.9 ± 4.2 |
| Swollen joint count | 1.1 ± 2.4 |
| DAS28 | 3.0 ± 1.1 |
| Erosion, n (%) | 77 (24.1) |
| Visual analogue score | 6.4 ± 2.1 |
| ESR, mm/hr | 15.7 ± 15.1 |
| CRP, mg/dL | 0.8 ± 1.6 |
| Positive rheumatoid factor, n (%) | 244 (76.3) |
| Medication history | |
| Current dose of glucocorticoids, mg | 1.4 ± 1.3 |
| Cumulative dose of glucocorticoids, g | 3.6 ± 4.1 |
| MTX, n (%) | 192 (59.8) |
| Hydroxychloroquine, n (%) | 163 (50.8) |
| Leflunomide, n (%) | 39 (12.2) |
| TNF inhibitor, n (%) | 23 (7.2) |
| JAK inhibitor, n (%) | 45 (14.0) |
| NSAID use, n (%) | 240 (74.8) |
| Osteoporosis, n (%) | 141 (44.1) |
| Total muscle mass, kg/m2 | 26.87 ± 11.1 |
| Fat free mass index, kg/m2 | 18.1 ± 5.8 |
| aLM, kg/m2 | 7.3 ± 1.1 |
| Mean strength of grip, kg | 19.3 ± 5.8 |
| Walk speed, m/s | 0.8 ± 0.2 |
| Presarcopenia by the EWGS, n (%) | 54 (16.9) |
| Sarcopenia by the EWGS, n (%) | 21 (6.6) |
| Sarcopenia by the AWGS, n (%) | 7 (2.2) |
| Sarcopenia by the SARC-F, n (%) | 38 (11.9) |
RA, rheumatoid arthritis; SD, standard deviation; BMI, body mass index; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; MTX, methotrexate; TNF, tumor necrosis factor; JAK, Janus kinase; NSAID, non-steroid anti-inflammatory drugs; aLM, appendicular lean mass index; EWGS, European Working Group for Sarcopenia; AWGS, Asian Working Group for Sarcopenia; SARC-F, sluggishness, assistance in walking, rising from a chair, climb stairs, falls. Values are mean ± SD or n (%).